Biotechs targeting cancer, immunology likely to draw buyout bids

07/13/2011 | Reuters

Biotech companies that specialize in drugs for cancer, immune system diseases and brain conditions are likely to become attractive acquisition targets for Big Pharma, said investment bankers and other industry experts. Among such firms are Seattle Genetics, which has a drug candidate for two rare types of blood cancer, and Biogen Idec, which has multiple sclerosis drugs on the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN